Most notably, oral administration of erythromycin in the HSALR DM1 mouse model at the equivalent therapeutic dose currently being used in humans, significantly rescued mis-splicing of several events, including Clcn1 exon 7a and Atp2a1 exon 22, and partially rescued myotonia [46]. The gene discussed is ATP2A1; the disease is myotonic dystrophy type 1.